Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557619 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
A Phase 1 study of Hematologic Malignancies, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 4
- Study locations
NCT03557619 is a Phase 1 study of Hematologic Malignancies that is actively recruiting participants, run by AbbVie. The registered enrollment target is 12 participants, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03557619, a Phase 1 study of Hematologic Malignancies, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and without any clinically significant evidence of disease progression with no access to venetoclax (not approved for the treated indication) may continue receiving venetoclax at the discretion of the investigator in a separate extension study.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG ethinyl estradiol/levonorgestrel
Study Locations (4)
Michigan
- Duplicate_Henry Ford Health System /ID# 209090 - Detroit
New Hampshire
- Dartmouth-Hitchcock Medical Center /ID# 169097 - Lebanon
Ohio
- Gabrail Cancer Center Research /ID# 207039 - Canton
Victoria
- Peter MacCallum Cancer Centre-East Melbourne /ID# 225247 - East Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2026-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03557619
The ClinicalTrials.gov registry entry for NCT03557619 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (100% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT03557619 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Michigan, New Hampshire, Ohio.
Frequently Asked Questions
What is clinical trial NCT03557619 about?
NCT03557619 is a clinical study titled "A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies". A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and...
What is the current status of trial NCT03557619?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-07-30. Estimated completion is 2026-03-21.
What conditions does trial NCT03557619 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT03557619?
The interventions under investigation include: Venetoclax (DRUG), ethinyl estradiol/levonorgestrel (DRUG).
Who is sponsoring clinical trial NCT03557619?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03557619 being conducted?
This trial has 4 study locations across Michigan, New Hampshire, Ohio, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
RECRUITING · Phase 1
-
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.